As­traZeneca eyes a safer PARP in­hibitor, with near­ly 50% re­sponse in ad­vanced breast can­cer pa­tients: #AACR24

SAN DIEGO — As­traZeneca’s ex­per­i­men­tal PARP1 in­hibitor helped shrink tu­mors in near­ly half of peo­ple with breast can­cers har­bor­ing cer­tain DNA re­pair de­fects in an ear­ly …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER